Form 8-K ZS Pharma, Inc. For: Nov 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
JPMorgan Downgrades ZS Pharma (ZSPH) to Neutral
November 9, 2015 7:17 AM ESTJPMorgan downgraded ZS Pharma (NASDAQ: ZSPH) from Overweight to Neutral with a price target of $90.00 (from $75.00).
For an analyst ratings summary and ratings history on ZS Pharma click here. For more ratings news on ZS Pharma click here.
Shares of ZS Pharma closed at $89.04 yesterday.
... MoreAstraZeneca (AZN) to Acquire ZS Pharma (ZSPH) in $2.7B Deal
November 6, 2015 6:36 AM ESTAstraZeneca (NYSE: AZN) announced today that it has entered into a definitive agreement to acquire ZS Pharma (NASDAQ: ZSPH), a biopharmaceutical company based in San Mateo, California. ZS Pharma uses its proprietary ionÂ-trap technology to develop novel treatments for hyperkalaemia (high potassium levels), a serious condition of elevated potassium in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure (CHF).
The transaction will give AstraZeneca access to the potassium-binding compound ZS-9, a potential best-in-class treatment for hyperkalaemia, a condition... More
